Clinical Trials Logo

Renal Cancer Metastatic clinical trials

View clinical trials related to Renal Cancer Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05285579 Recruiting - Clinical trials for Renal Cell Carcinoma

Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer

ANGIOCOR
Start date: May 5, 2022
Phase:
Study type: Observational

This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell carcinoma treated by a combination of immunotherapy and antiangiogenic.

NCT ID: NCT05215470 Recruiting - Clinical trials for Renal Cancer Metastatic

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Start date: January 18, 2022
Phase: Phase 2
Study type: Interventional

The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).

NCT ID: NCT03736330 Recruiting - Clinical trials for Renal Cancer Metastatic

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Start date: September 8, 2018
Phase: Phase 2
Study type: Interventional

Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma treated with axitinib.

NCT ID: NCT03628859 Recruiting - Clinical trials for Renal Cancer Metastatic

BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)

BIOREN
Start date: December 21, 2018
Phase:
Study type: Observational

The BIOREN project aims are to characterize the genetic background of renal cell carcinomas and their immune environment, to try and identify biomarkers of response and to better understand the mechanisms of resistance to nivolumab in renal cancer.

NCT ID: NCT03469713 Completed - Clinical trials for Renal Cancer Metastatic

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

NIVES
Start date: July 14, 2017
Phase: Phase 2
Study type: Interventional

NIVES study is an ongoing phase II, single arm, multicenter study. In this trial pts received SBRT to one non-brain measurable lesion and concomitant NIVOLUMAB, an anti-programmed cell death (PD-1). Combining SBRT with NIVO may enhance the antitumor immune responses and improve clinical outcomes, how it was demonstrated for other solid tumors with a phenomenon known as the abscopal effect . It was planned to enrolled a total of 68 pts within 12 months. The objective of the current analysis is to describe the first report of safety profile of NIVO in combination with SBRT.